Latest
Univest Analyst action
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–36
- Matches
- 126
- Sources here
- 18
- Companies here
- 6
Search results
Stored financial headlines
Active search
126 matching headlines
Ticker or company: BIKMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants
Sands Capital Life Sciences Pulse Fund II, L.P., along with related entities, has reported a beneficial ownership of 9.3% in Inhibikase Therapeutics, Inc. This stake includes 13,018,965 shares of common stock and substantial warrants for an additional 15.5 million shares, although these warrants are …
IKT
main company
Sharemaestro market context
Trend signal active
52 weeks +27.5%
Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5
Oppenheimer has reiterated its Buy rating on Inhibikase Therapeutics (IKT.US), maintaining a target price of $5. This indicates continued confidence from the firm in the company's prospects.
IKT
main company
Sharemaestro market context
Trend signal active
52 weeks +27.5%
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics announced its Q2 2026 financial results, reporting a net loss of $19.6 million and $159.0 million in cash and marketable securities. The company highlighted significant progress in its Phase 3 IMPROVE-PAH study for IKT-001, including regulatory approvals in 26 countries and recent …
IKT
main company
Sharemaestro market context
Trend signal active
52 weeks +27.5%
Inhibikase Q2 Results: Net Loss Widens to $19.6 Million
Inhibikase Therapeutics reported a Q2 2026 net loss of $19.6 million, or $(0.11) per share, which met analyst estimates but widened from the previous year due to increased R&D spending for its Phase 3 PAH program. The company also raised $50 million through a …
IKT
main company
Sharemaestro market context
Trend signal active
52 weeks +27.5%
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Inhibikase Therapeutics, Inc. is projected to report a loss of 11 cents per share in its upcoming earnings. This article serves as an earnings preview, indicating the anticipated financial performance for the company.
IKT
main company
Sharemaestro market context
Trend signal active
52 weeks +27.5%
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has received a consensus "Buy" recommendation from nine brokerages, with an average 12-month price target of $5.40. The company's shares recently opened at $2.47, up 2.5%, with a market capitalization of $326.11 million. Several institutional investors, including Goldman Sachs Group …
IKT
main company
Sharemaestro market context
Trend signal active
52 weeks +27.5%